T follicular helper cells in cancer

N Gutiérrez-Melo, D Baumjohann - Trends in cancer, 2023 - cell.com
T follicular helper (Tfh) cells provide essential help to B cells for effective antibody-mediated
immune responses. Although the crucial function of these CD4+ T cells in infection and …

Immunomodulation by targeted anticancer agents

G Petroni, A Buqué, L Zitvogel, G Kroemer, L Galluzzi - Cancer cell, 2021 - cell.com
At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

T Siddiqi, JD Soumerai, KA Dorritie… - Blood, The Journal …, 2022 - ashpublications.org
Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly
diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic …

BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance

L Zhao, P Liu, M Mao, S Zhang, C Bigenwald… - Cancer discovery, 2023 - AACR
We developed a phenotypic screening platform for the functional exploration of dendritic
cells (DC). Here, we report a genome-wide CRISPR screen that revealed BCL2 as an …

Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia

KA Rogers, Y Huang, AS Ruppert… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The development of highly effective targeted agents for chronic lymphocytic
leukemia offers the potential for fixed-duration combinations that achieve deep remissions …

T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?

PM Roessner, M Seiffert - Leukemia, 2020 - nature.com
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, which is associated with
profound alterations and defects in the immune system and a prevalent dependency on the …

[HTML][HTML] Targeting the tumor microenvironment in chronic lymphocytic leukemia

R Svanberg, S Janum, PEM Patten, AG Ramsay… - …, 2021 - ncbi.nlm.nih.gov
The tumor microenvironment (TME) plays an essential role in the development, growth, and
survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL). Within the …

Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape

M Mangolini, A Maiques-Diaz… - Nature …, 2022 - nature.com
Hotspot mutations in the PEST-domain of NOTCH1 and NOTCH2 are recurrently identified
in B cell malignancies. To address how NOTCH-mutations contribute to a dismal prognosis …

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

H Huber, E Tausch, C Schneider, S Edenhofer… - Blood, 2023 - ashpublications.org
The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response
and tolerability of the triple combination of obinutuzumab, ibrutinib, and venetoclax (GIVe …

Cytotoxicity of the CD3× CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

M Mhibik, EM Gaglione, D Eik, J Herrick, J Le… - Blood …, 2023 - ashpublications.org
Chronic lymphocytic leukemia (CLL) is an immunosuppressive disease characterized by
increased infectious morbidity and inferior antitumor activity of immunotherapies. Targeted …